Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. LXEO
LXEO logo

LXEO

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

LXEO News

Lexeo Therapeutics Announces Investor Conference Schedule

Feb 05 2026Newsfilter

Lexeo Therapeutics Announces Key Senior Leadership Appointments

Jan 27 2026Newsfilter

Telsey Raises Five Below Inc Price Target to $240

Jan 13 2026Benzinga

U.S. Stocks Mixed; Day One Biopharmaceuticals Shares Surge 20%

Jan 12 2026Benzinga

IBM and LXEO Options Show Significant Volume Surge

Jan 09 2026NASDAQ.COM

Lexeo Therapeutics Partners with J&J to Advance Gene Therapy for Cardiovascular Diseases

Jan 08 2026NASDAQ.COM

Valvoline Analyst Starts Coverage Optimistically; Check Out Thursday's Top 5 Initiations

Dec 18 2025Benzinga

Biotech Sector Sustains After-Hours Trading Gains

Dec 18 2025NASDAQ.COM

Lexeo Therapeutics to Host Virtual Event on Managing PKP2-Associated Arrhythmogenic Cardiomyopathy

Dec 04 2025Globenewswire

Chardan Capital Reaffirms Buy Rating on Lexeo Therapeutics with $17 Price Target Intact

Nov 06 2025Benzinga

Innovative Approaches to Address Challenging Medical Conditions Beyond Conventional Medications

Oct 21 2025Newsfilter

Lexeo Therapeutics Reveals Pricing for Public Offering and Simultaneous Private Placement

Oct 17 2025Newsfilter

Lexeo Therapeutics Unveils Plans for Common Stock and Pre-Funded Warrants Offering

Oct 16 2025Newsfilter

Top Analysts Recommend 3 Best Stocks to Purchase Now, 10/15/2025

Oct 15 2025TipRanks

Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034

Oct 08 2025PRnewswire

Lexeo Therapeutics Reports Advancements in FDA Talks for Fast-Track Approval and Encouraging Interim Clinical Results for LX2006 in Friedreich Ataxia Cardiomyopathy

Oct 07 2025Newsfilter